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Abstract 
Human Disc large (DLG1) is a scaffolding protein that through the interaction with diverse 
cell partners participates in the control of key cellular processes such as polarity, proliferation 
and migration. Experimental data have mainly identified DLG1 as a tumor suppressor. An 
outstanding point for DLG1 protein is that altered DLG1 expression and DLG1 gene 
mutations were observed in different pathologies, including cancer and neurological and 
immunological disorders. Evident changes in DLG1 abundance and/or cell localization were 
identified in a number of studies suggesting its participation in molecular mechanisms 
responsible for the development of such illnesses. In this review, we focus on some of the 
latest findings regarding DLG1 alterations in different diseases as well as its potential use as a 
biomarker for pathological progression. We further address the current knowledge on the 
molecular mechanisms regulating DLG1 expression and the posttranslational modifications 
that may affect DLG1 cell localization and functions. Despite the advances in this field, there 
are still open questions about the precise molecular link between alterations in DLG1 
expression and the development of each specific pathology. The complete understanding of 
this concern will give us new scenarios for the design of promising diagnosis and therapeutic 
tools. 
Keywords: cancer; DLG1; expression; inflammation; neurological disorders; regulation. 
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Introduction 
The polarity protein discs large 1 (DLG1) belongs to the family of molecular scaffolding 
proteins known as Membrane Associated Guanylate Kinases (MAGUKs). As the other family 
members, DLG1 contains multi-PDZ (PSD95/DLG/ZO-1) domains, a Src homology 3 
interaction module and an enzymatically inert guanylate kinase domain. An accumulating 
body of evidence indicates that the modular organization and scaffolding properties of 
MAGUKs play crucial roles in important cellular processes and features of different cell 
types, like the regulation of signaling pathways which are linked to the control of tissue 
growth, differentiation, cell migration and cell architecture plasticity (Won et al., 2017).  
DLG1 is a component of the conserved Scribble polarity complex. Genetic and functional 
analyses highlighted the relevance of DLG1 in cell processes which require intracellular 
asymmetry, including the establishment and maintenance of cell polarity, as well as 
asymmetric cell division and cell migration (Knoblich, 2008; O’Neill et al., 2011; Golub 
et al., 2017; Stephens et al., 2018). In epithelial cells, DLG1 is localized to the adherens 
junctions in association with components of the cytoskeleton, where it coordinates junction 
formation and stability while contributing to the maintenance of apical-basal polarity (Laprise 
et al., 2004). Several mammalian DLG1 binding partners have been identified and many of 
them are key regulators of cellular signaling networks, highlighting the significant role of this 
scaffolding protein in mammalian cells. In addition, DLG1 was shown to be targeted by 
multiple human viral oncoproteins including the human papillomavirus (HPV) E6, the 
adenovirus E4-ORF1, and the human T cell leukemia virus type 1 (HTLV-1) Tax (Gardiol 
et al., 1999, Gardiol et al., 2002; Hirata et al., 2004; Kong et al., 2014; Marziali et al., 2017). 
These interactions have been implicated in the transforming and tumorigenic properties of the 
viral oncoproteins, giving DLG1 a key participation in viral pathogenesis. However, other 
works stand for the idea of DLG1 contributing to human epithelial cancers unrelated to viral 
infections as well. 
Loss of apicobasal polarity has been recognized as a fundamental step in tumorigenesis. In 
this regard, initial experiments in Drosophila demonstrated that lack of DLG1 expression 
leads to uncontrolled epithelial cell proliferation and neoplastic transformation, thereby 
defining DLG1 as a potential tumor suppressor. This hypothesis was extrapolated to 
mammals considering that epithelial cells from invasive carcinomas generally exhibit DLG1 
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null expression. Although DLG1 has historically been characterized as a tumor suppressor 
(Elsum et al., 2012; Sandoval et al., 2013) other studies challenged this notion. In fact, DLG1 
varies in expression among malignancies and is known to play different and sometimes 
opposing roles in processes involved in tumor progression, including differentiation, 
cytokinesis, proliferation, cell migration, and control of the microenvironment of the tumor 
(Roberts et al., 2012; James and Roberts, 2016; Stephens et al., 2018). These data suggest that 
DLG1 can acquire oncogenic attributes in some specific contexts; emphasizing the 
importance of DLG1 deregulation in human carcinogenesis, as described below.  
Even though most of the knowledge about DLG1 derives from experiments in the epithelial 
context, DLG1 is also expressed in cells from the nervous and immunological systems. In 
regards to the former, a growing number of reports have suggested DLG1 participation in 
several exocytotic and endocytotic pathways by directing components of the vesicle 
trafficking machinery either to the plasma membrane or to transport vesicles, regulating 
neuron receptor localization and clustering (Walch, 2013). Furthermore, DLG1 contributes to 
nerve cell functions by regulating various signaling pathways that organize the architecture 
and functionality of the synapses (Fourie et al., 2014). Meanwhile, the activity of DLG1 in 
immune cell biology has been ascertained for different T-cell types. In general, DLG1 
mediates signal transduction downstream to T-cell receptors by facilitating microtubule 
polarization at the immunological synapses and by bridging significant kinases with their 
phosphorylation targets in such cell region (Round et al., 2005; Lasserre et al., 2010). 
During the last years, different excellent revisions have addressed the plethora of interactions 
between DLG1 and cellular or viral partners that have contributed to explaining how DLG1 
participates in the processes explained above (Stephens et al. 2018; Saito et al., 2018). In this 
work, we will present the current knowledge about the expression of DLG1 in diverse human 
pathologies through alterations in its abundance and localization as well as specific genetic 
changes in the DLG1 gene. We will also discuss emerging evidence that supports a key dual 
role for DLG1 in cancer, with both oncogenic or tumor suppressor activities according to the 
biological scenario. Moreover, we will extend the analysis to pathologies related to 
neurological and inflammatory processes. Finally, we will summarize the available data on 
the regulation of DLG1 expression and its impact on the development of cancer and other 
human pathologies (Figure 1).  
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DLG1 Expression in different pathologies 
Epithelial cancer progression 
A particular interest in DLG1 is due to its altered expression during the malignant progression 
of epithelial tumors (Figure 1A). Initial evidence was gathered from the analysis of HPV-
induced cervical carcinogenesis. Cell culture experiments had shown that DLG1 was targeted 
for proteasomal degradation by the transforming oncoprotein E6 from High-risk HPV 
(Gardiol et al., 1999, Gardiol et al., 2002). Such findings prompted an investigation of DLG1 
expression in the evolution of cervical lesions. In this sense, immunohistochemistry assays 
revealed a loss of DLG1 expression in invasive stages of the disease (Watson et al., 2002; 
Cavatorta et al., 2004). The fact that HPV E6 oncogene were highly upregulated in such 
stages suggested DLG1 proteasomal degradation, which was then supported by experiments 
showing that cervical cancer cell lines restored DLG1 levels and localization at the cell 
borders upon E6 ablation or proteasome inhibition (Massimi et al., 2004). However, striking 
changes in DLG1 expression were also observed in the early onset of disease, namely the 
preceding low-grade intraepithelial lesions (LSIL). In certain LSIL cases, reduced localization 
at the cell borders was evidently accompanied by increased expression in the cytoplasmic 
region (Cavatorta et al., 2004; Cavatorta et al., 2017). Altogether, these initial analyses served 
to associate loss of DLG1 expression with cervical invasive stages, supporting the hypothesis 
of tumor suppressor functions of DLG1. Moreover, they also raised the possibility of a role of 
DLG1 mislocalization during the onset of cervical pathology. In addition, these analyses led 
to an interest to study the scenario in epithelial tumors unrelated to HPV infection. In this 
sense, biopsies from different colon adenocarcinomas were analyzed for DLG1 expression 
and, interestingly, some changes were detected. Semi-differentiated colon adenocarcinomas 
exhibited a reduction of DLG1 expression at the cell borders with a diffuse and increased 
cytoplasmic staining (Cavatorta et al., 2004; Gardiol et al., 2006). Furthermore, DLG1 protein 
was nearly undetectable in poorly differentiated stages. DLG1 expression was also analyzed 
in lung, larynx, breast and, more recently, in hepatocellular cancers. In all cases, a clear 
downregulation of its levels was found in late stages of malignancy (Fuja et al., 2004; Byeon 
et al., 2011; Szymanowska-Narloch et al., 2013; Wu et al., 2016). Moreover, in some of these 
reports, DLG1 upregulation and loss from cell borders were also observed, as well as 
mislocalization in intermediate lesions.  
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Taken together, the results described above suggest a common pattern for DLG1 expression 
during epithelial tumor evolution. Loss of DLG1 expression could indeed be considered a late 
stage of epithelial malignancy. On the other hand, the loss of DLG1 from its regular site of 
cell–to-cell interactions, accompanied by eventual overexpression, may take place in less 
severe lesions. The intriguing question of possible effects of such misexpression on the 
pathology outcome (better or worse prognosis) have been addressed in some exciting recent 
works. In the case of cervical cancer, our group performed a follow-up analysis associating 
the DLG1 staining pattern at LSIL stage with progression of malignancy or regression to a 
normalization of the epithelium (as frequently occurs at this stage). Interestingly, all LSIL 
cases with a membrane-associated DLG1 staining, resembling that of a normal tissue, 
regressed. However, LSILs with DLG1 misdistribution and overexpression progressed to 
high- grade intraepithelial lesions. In another study which analyzed colorectal tumor samples, 
increased and cytoplasmic expression of DLG1 was closely associated with malignancy (Zhu 
et al., 2017). Interestingly, such patients suffered a more aggressive form of the disease being 
reflected on enhanced tumor evasion and low overall survival. Finally, research carried out in 
endometrial cancer tissues showed that patients with DLG1 cytoplasmic staining were linked 
to nodal metastasis and poorer overall survival than those with a strong or weak membrane-
associated expression (Sugihara et al., 2016). Therefore, these data clearly suggest that DLG1 
misexpression is highly associated with tumor progression or more malignant forms of the 
disease. Considering DLG1 scaffolding properties, it is possible that its contribution or 
implication in cancer relates to its inability to interact with the correct partners in a 
spatial/temporal manner. Since DLG1 redistribution to the cytoplasm is normally achieved 
during the S phase of the cell cycle, this pattern of expression could be associated with a 
proliferative state of epithelial cells. In the context of a tumor cell, such misexpressions are 
likely to synergize with abnormal expression of wild-type or mutated oncogenes in order to 
fully contribute to cell transformation. In this line, more studies are necessary to understand 
the precise mechanism by which DLG1 deregulation contributes to malignancy. Nevertheless, 
it is important to note that the DLG1 staining pattern could serve to predict evolution of 
disease. 
Neurological disorders 
DLG1 contributes to the maintenance of neuronal homeostasis. DLG1 participates in the 
trafficking of glutamate and aspartate receptors and α-subunits of the potassium channels 
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Kv1.4 and Kv 4.2 to the cell membrane, all of which are crucial for basal synaptic 
transmission and synaptic plasticity (Gardoni et al., 2007; Fourie et al., 2014). Accordingly, 
there is mounting evidence that associates DLG1 deficiency or DLG1 mutant variants with 
the development of a number of neurological disorders (Figure 1B) (Soler et al., 2018). 
Perhaps the best defined is Schizophrenia (SZ), which relies on altered glutamate 
neurotransmission (Sato et al., 2008; Uezato et al., 2012). Studies analyzing schizophrenic 
post-mortem brains reported a marked loss of DLG1 expression in the prefrontal cortex 
region. Microdeletions in the 3q29 locus, which contains DLG1 gene, were found in such 
patients (Toyooka et al., 2002; Mulle et al., 2010; Quintero-Rivera et al., 2010; Kirov et al., 
2012; Glassford et al., 2016). More recently, additional causes that may contribute to SZ 
susceptibility in regards to DLG1 expression have been reported. A study employing DNA 
methylation chip arrays demonstrated changes in the methylation pattern of DLG1 gene and 
the upstream region, whereas other reports showed SZ-associated non-synonymous single 
nucleotide variants (SNVs) within the DLG1 coding sequence (Purcell et al., 2014; Fromer 
et al., 2014; Xing et al., 2016; McKinney et al., 2017). Remarkably, similar genetic variations 
in DLG1 gene were demonstrated in further neurological pathologies. SNV and microdeletion 
were observed in autism-spectrum disorders while single nucleotide polymorphisms (SNP, 
which represent SNV that are at least as 1% frequent in population) were detected in cases of 
frontotemporal dementia. This last disorder affects the frontal-temporal lobes of the brain and 
is linked to progressive deterioration of behavior and cognition (Rabinovici and Miller, 2010). 
Interestingly, abnormal hypomethylation state of DLG1 promoter region was also found in 
this pathology (Taskesen et al., 2017).  
Parkinson disease (PD) is a degenerative disorder of the central nervous system, and the 
etiological causes are poorly known. In animal models, a reduced expression and altered 
cellular distribution of the rat DLG1 homologue, SAP97, was observed in Parkinson drug 
induced experiments (Nash et al., 2005). Furthermore, microarray studies analyzing gene 
expression in whole blood identified DLG1 as a candidate gene for PD (Sun et al., 2014). 
These reports suggest a potential involvement of DLG1 misexpression in the pathobiology of 
this neurological disorder. 
Finally, interstitial microduplication of 3q29 has been recently described in patients with 
widely variable phenotypes. A case-report study described a 1.607 Mb duplication at 3q29 
locus, involving several genes including DLG1, in an individual with intellectual disability, 
epilepsy, and cerebral palsy. The association of this genetic change with DLG1 expression 
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level and with these severe clinical manifestations requires further investigation to understand 
whether or not DLG1 dysfunctions could play a role in these syndromes (Fernández-Jaén 
et al., 2014). 
Inflammatory and autoimmune diseases 
Regulatory T cells (Tregs) are central players in maintaining immune tolerance to self-
antigens, preventing autoimmune diseases (Kitagawa and Sakaguchi, 2017). Treg 
immunosuppressive functions rely on TCR engagement and activation of downstream 
signaling pathways (Li and Rudensky, 2016). Evidence suggests that DLG1 accumulation at 
the immunological synapse (IS) must be particularly important for Tregs activation since 
these cells were shown to recruit a fourfold higher level of DLG1 than other T-cell types 
(Zanin-Zhorov et al., 2012; Zanin-Zhorov et al., 2017). Importantly, DLG1 was demonstrated 
to modulate both nuclear factor of activated T cells (NFAT) and phosphatidylinositol 3-kinase 
(PI3K)/protein kinase B (Akt) signaling pathways whose precise regulation is necessary for 
proper Treg functions. In this regard, DLG1 interacts to p38 MAP kinase and stimulates its 
activity which is required for NFAT activation and immunosuppressive cytokine production. 
In addition, DLG1 confers stability to PTEN phosphatase, which in turn downregulates the 
PI3K activity that normally impairs Treg functions (Zanin-Zhorov et al., 2012; Zanin-Zhorov 
et al., 2017).  
Current evidence indicates an association of autoimmune and inflammatory diseases with a 
reduced capacity of Tregs to recruit sufficient amount of DLG1 at IS. One example is 
rheumatoid arthritis (RA), an autoimmune disease where diminished activity of Tregs has 
been observed. In RA patients Tregs are defective in suppressing CD8+ T-cell proliferation 
and, surprisingly, they were shown to accumulate lower levels of DLG1 at IS than Tregs from 
healthy individuals (Figure 1C) (Zanin-Zhorov et al., 2012). A similar scenario might occur in 
patients with the neuro-inflammatory disease known as HTLV-1-associated myelopathy/ 
Tropical spastic paraparesis (HAM/TSP). This pathology is linked to HTLV-1 infection and is 
characterized by a high infiltration of HTLV-1 infected Tregs into the central nervous system. 
Interestingly, such cells not only present low suppressive activity but also change to a pro-
inflammatory phenotype (Araya et al., 2014). This phenomenon was explained in part by the 
activity of the HTLV-1 Tax protein, a key player for HTLV-1 replication, which is expressed 
at high levels in HAM/TSP (Araya et al., 2011; Enose-Akahata et al., 2017). HTLV-1 Tax 
has been reported to downregulate foxp3 expression (a transcription factor crucial for Tregs 
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suppressive activities); however, it may use further mechanisms to interfere with Tregs 
functions. In this regard, we and others have demonstrated that Tax can directly interact with 
DLG1 and promote its hyperphosphorylation leading to DLG1 mislocalization from the cell 
borders to the MTOC/Golgi region (Figure 1C) (Hirata et al., 2004; Marziali et al., 2017) . 
Thus, this interaction might interfere with DLG1 accumulation at IS upon TCR engagement, 
negatively affecting suppressive responses of infected Tregs. Interestingly, HAM/TSP 
individuals have a tendency to develop RA and studies using transgenic mouse models have 
confirmed a role of HTLV-1 Tax in the onset of such disease (Habu et al., 1999; Yakova 
et al., 2005). 
Mechanisms of regulation of DLG1 expression 
The above-mentioned facts remark the importance of DLG1 functions, and most likely of its 
interactions in specific areas of the cell in different cell types and tissues. Although the 
emergent interest in DLG1 deregulation as a central matter in the development of pathologies 
and in the identification of prognostic biomarkers, the molecular mechanisms that control 
DLG1 levels and localization, in physiological or pathological conditions, are still poorly 
understood. In the following sections we will discuss the current state of knowledge on the 
mechanisms that may contribute to regulating DLG1 protein abundance and cell distribution 
(Figure 2). 
Transcriptional level 
The first attempt to identify elements regulating DLG1 expression was carried out by cloning 
the minimal region with promoter activity upstream from the transcription start site initially 
reported by Lue and collaborators (Lue et al., 1994; Cavatorta et al., 2008). A detailed 
analysis of such region revealed the presence of several consensus binding sites for 
transcription factors like Nuclear factor kappa B, AP-1, AP-2, SP-1, Snai1 (Cavatorta et al., 
2008). More recently, a study has added the human zinc finger 191 (ZNF191) factor to the list 
(Wu et al., 2016). Although their functions have been well studied, the influence on DLG1 
promoter has only been ascertained for Snai1 and ZNF191 (Figure 2A). 
Snai1 is a transcription factor member of the Snail family which participates actively in the 
epithelial-mesenchymal transition (EMT) during embryonic development, driving epithelial 
cell migration. Reactivation of EMT is one of the most striking features of epithelial tumor 
cells in advanced stages of malignancy. This can be triggered by the tumor environment 
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through secretion of cytokines like Epithermal Growth Factor, Transforming Growth Factor-
beta, Notch, Wnt and Tumor Necrosis factor-alpha. In response to such signals, epithelial 
tumor cells upregulate the EMT promoting factor Snai1 (Wang et al., 2013). Interestingly, 
Snai1 was shown to downregulate DLG1 expression by interacting with E-box-like elements 
present in DLG1 promoter and repressing gene transcription (Cavatorta et al., 2008). 
Therefore, the observed decrease in DLG1 levels frequently reported in advanced stages of 
epithelial tumors may be, in part, a consequence of EMT program reactivation triggered by 
Snai1. 
DLG1 expression was recently found to be also regulated by the transcription factor ZNF191, 
which plays a role in mammal embryonic development as well as in adult organs (Li et al., 
2009). In hepatocytes, ZNF191 inhibits migration by downregulating the Hippo-Yes-
associated protein (YAP) signaling pathway. More specifically, ZNF191 promotes the 
cytoplasmic retention of the signaling activator YAP through phosphorylation. Strikingly, 
ZNF191-mediated YAP phosphorylation was shown to depend on DLG1 expression, 
suggesting a functional link between ZNF191 and DLG1 during HIPO-YAP signaling 
regulation. This relationship was clarified having found that ZNF191 interacts with TCAT 
repetitive motifs on DLG1 promoter and activates its transcription (Wu et al., 2016). 
Importantly, ZNF191 was found to be downregulated in invasive hepatocellular carcinoma. 
Hence, this fact could strongly contribute to understanding the loss of DLG1 expression found 
in such stages of malignancy (Wu et al., 2016).  
Finally, the promoter region of DLG1 presents sequences enriched with CpG dinucleotides. 
Such elements allow transcription from different start sites giving rise to pools of mRNA for 
DLG1 with high variability in the 5´ extreme, however, the usage of particular sites under 
different biological contexts has not yet been studied (Cavatorta et al., 2011). In addition, 
CpG dinucleotides allow epigenetic control by hipo or hyper-DNA methylation. Nevertheless, 
to date no studies have deeply analyzed how the epigenetic status of DLG1 promoter relates 
to DLG1 protein levels. This knowledge, as well as the identification of epigenetic regulators, 
could be particularly important for the neurological disorders explained before. 
Post-transcriptional level 
Genes that must be precisely regulated, such as oncogenes and genes encoding transcription 
factors, receptors, transduction pathway regulators and tumor suppressors, often give rise to 
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transcripts with variable 5' untranslated regions (5´UTR) (Hughes, 2006; Willimott and 
Wagner, 2010; Ishii and Sakuma, 2011). DLG1 could be placed in such category since a 
5´UTR alternative splicing event was identified in that region (Figure 2B). Such mechanism 
was detected in different cell types, highlighting its conserved nature. Of note, the spliced 
exon contains two elements that regularly have a negative influence on translation efficiency: 
a short upstream open reading frame (uORF) and stable stem loops. uORF are genetic 
elements reported to decrease translation rate of main ORFs by reducing the availability of 
ribosomes. On the same hand, stem loops within 5´UTR provoke ribosome stalling and may 
also create binding sites for cellular factors that affect translation efficiency (Smith, 2008; 
Hinnebusch et al., 2016). Importantly, the negative impact of both elements on DLG1 
expression was confirmed having found a higher translation efficiency for the spliced variant 
(Cavatorta et al., 2011). These findings opened the possibility of 5´UTR splicing as a 
mechanism to regulate DLG1 levels in biological contexts in which DLG1 plays an important 
role. In this regard, an upregulation of 5´UTR spliced version relative to the unspliced form 
was observed during adherens junction formation of colon epithelial cells, where an increase 
in DLG1 levels has been reported (Marziali et al., 2015). However, a less significant role of 
this mechanism was found in DLG1 decreased levels observed during cell cycle progression 
from G1 to S phase (Marziali et al., 2015). Therefore, these data revealed that the extent of 
5´UTR splicing as a mechanism to control DLG1 protein levels is highly dependent of 
specific cellular behaviors. Thus, it is tempting to speculate that interferences in this 5´UTR 
splicing mechanism could have potential to contribute to oncogenic processes by increasing 
or decreasing DLG1 levels depending on the tumoral context. 
Post-translational level 
DLG1 plays an important role in the organization of signaling pathways recruiting several 
kinases at specific cell regions and supporting the availability of substrates near the kinase 
active sites. In turn, phosphorylation is a major post-translational modification that controls 
DLG1 activities, interacting partners and cellular localization. Many different phosphorylation 
events by diverse kinases were described for DLG1 with different outcomes in DLG1 
functions (Figure 2C). 
DLG1 is important for cell regulation and it was shown to be phosphorylated in cells exposed 
to different stress signals. Under hyperosmotic stress eukaryotic cells may shrink and cells 
may develop responses to restore cell integrity, volume, and homeostasis. For this, several 
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signalling pathways are activated in order to reinforce and modulate the cytoskeletal network. 
Particularly, the p38 mitogen-activated protein kinases (MAPKs) are stimulated and 
specifically, SAPK3/p38gamma activation is rapid and strong compared to other p38s (Sabio 
et al., 2004). It was shown that DLG1 is a substrate of this kinase and this phosphorylation 
prompts the dissociation of DLG1 from the guanylate kinase-associated protein (GKAP). 
GKAP interacts with intermediate filaments and is able to associate with DLG1 and recruit it 
to the cytoskeleton. Phosphorylated DLG1 by osmotic shock may suffer conformational 
changes that prevent its interaction with GKAP and induce its release from the cytoskeletal 
fraction, probably for regulating intercellular complexes and polarity under changes in the 
extracellular environment (Sabio et al., 2005). In line with this study, Massimi and colleagues 
demonstrated that the osmotic shock induces the phosphorylation of DLG1 in parallel with its 
accumulation in the cells´ borders, at sites of cell-to-cell junctions, suggesting that the release 
of DLG1 from the cytoskeleton could contribute to the maintenance of cell contacts under 
stress conditions (Massimi et al., 2006). This idea was also supported by the fact, that under 
osmotic shock, DLG1 moves to the insoluble fraction of the protein cell extracts, most likely 
because of its participation in molecular complexes with membrane–associated proteins. In 
this study, the phosphorylation sites were mapped within the first 185 aminoacids, and it was 
shown that the Jun N-terminal kinase (JNK) was responsible for DLG1 relocalization. 
Moreover, the redistribution of DLG1 to the cell junctions renders this protein more 
susceptible to proteasome degradation in the presence of HVP E6 oncoprotein; hence, 
phosphorylation may not only control DLG1 cell distribution but also its stability (Massimi 
et al., 2006). 
It was shown that phosphorylation can also control particular DLG1 functions in specific cell 
types. As described before, in T cells DLG1 localizes at the IS and controls TCR signal 
transduction by interacting with cytoskeletal and signaling regulators through its several 
interacting protein domains (Xavier et al., 2004). In CD8+ T cells, DLG1 directs TCR 
stimulation to the activation of pro-inflammatory cytokine gene expression and cytotoxic 
granule release, processes necessary for destroying infected or transformed cells which 
require the activation of different signal networks. In these cells, DLG1AB, an alternative 
spliced isoform of DLG1, is tyrosine phosphorylated (Y222) by LCK kinase after TCR 
activation (Silva et al., 2015). This specific modification renders DLG1 able to modulate p38 
activation and the subsequent cytokine expression, highlighting the importance of this 
posttranslational modification as a key control for the DLG1 activities involved in 
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lymphocyte biology. Moreover, blocking of DLG1AB phosphorylation was proposed as a 
novel therapeutic tool to specifically block proinflammatory cytokine production (Crocetti 
et al., 2014) 
DLG1 is able to interact with some tumour suppressors, such as Adenomatous polyposis coli 
and PTEN, and it was shown to regulate cell proliferation in many contexts. Hereafter, the 
regulation of DLG1 during the cell cycle should be important in order to strictly control cell 
growth.  
The first report about DLG1 in association with kinases during cell replication showed that 
the PDZ binding kinase (PBK) interacts with DLG1 PDZ domains and this interaction should 
be important for the association of this kinase with the central spindle and the promotion of 
cytokinesis. Both PBK and DLG1 were shown to be phosphorylated at mitosis in HeLa cells, 
and the mitotic phosphorylation of PBK by cyclin B/cdc2 was required for its activity. These 
initial findings suggested a link for DLG1 to signal transduction pathways regulating the cell 
cycle or cellular proliferation (Gaudet et al., 2000). Afterwards, an analysis of DLG1 
expression during the cell cycle identified that DLG1 localized at the cell junctions in G1, in 
the cytoplasm in S phase, relocating to the mitotic spindle in M phase and finally 
accumulating in the midbody during cytokinesis, demonstrating a cell cycle–dependent 
distribution of DLG1 that may impact on the protein activities. It was also shown that both 
cyclin dependent kinase 1 and 2 (CDK1 and CDK2) phosphorylate DLG1 on Ser158 and 
Ser442. These phosphorylation events modulate DLG1 nuclear localization, and particularly, 
protein stability, together with the redistribution of DLG1 to the mitotic spindle. These 
findings demonstrated the importance of cell cycle phosphorylation in the regulation of DLG1 
localization and abundance during the different phases with potential consequences on its 
oncosuppressor functions (Narayan et al., 2009). 
Others authors have also reported the phosphorylation of DLG1 at multiple sites during 
mitosis, like Ser102, Ser122 and Ser158. However, using specific phospho-antibodies the 
authors showed that, while DLG1 is accumulated at the midbody, phospo-DLG1 is absent 
from such structures, suggesting that phosphorylation may induce the dissociation of DLG1, 
likely by changing the protein binding pattern. Moreover, these authors also demonstrated that 
DLG1 phosphorylation in M phase is regulated by the ERK pathway which is involved in cell 
cycle control, potentially linking DLG1 to the regulation of entry and progression of mitosis 
(Inesta-Vaquera et al., 2010). 
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These data remark the presence of several sites in DLG1 that could be phosphorylated by 
diverse kinases, either independently or simultaneously, depending on the activated signal 
pathways, cell type, and extracellular microenvironment.  
As described above, DLG1 seems to have a dual role in oncogenesis with both oncogenic or 
tumour suppressor activities, according to the biological context. It is likely to hypothesize 
that the phosphorylation status could be a way of controlling such activities since the 
activation of many kinases depends on the stimulation of signal translation pathways involved 
in the regulation of tumour development or prevention. In line with this, Protein kinase C α 
isoform (PKCα) interacts with DLG1 in a PDZ-dependent manner and is able to 
phosphorylate DLG1 in the Thr-656 site. This phosphorylation correlates with increased 
invasiveness in non-small cell lung cancer lines and this event was considered a marker of 
PKC-mediated invasion, showing the requirement of DLG1 for PKCα to promote cellular 
migration. PKCα and DLG1 colocalize at the leading edge of the migrating cells and this 
depends on PKCα activity. These findings emphasize the involvement of DLG1 
phosphorylation in both DLG1 cell distribution and functions, in this particular case, 
contributing to PKCα mediated tumor progression and metastasis (O’Neill et al., 2011). 
Conclusions  
MAGUKs proteins are structurally and functionally conserved in many organisms, 
highlighting the relevance of their biological functions. Interestingly, the bulk of evidence 
summarized in this revision strengthen the hypothesis of a close association of changes in 
DLG1 expression or DLG1 gene mutations with diverse illnesses of high impact in public 
health, such as tumor development and neurological or immunological disorders.  
The identification of multiple cell partners of DLG1 contributed to understanding DLG1 
functions and its participation in key signal transduction pathways and diverse biological 
processes such as cell polarity maintenance, cell junction formation, cell proliferation and 
apoptosis (Roberts et al., 2012; Stephens et al., 2018). Hence, the finding of DLG1 
misexpression or DLG1 genetic alterations in tissues and cells derived from different illnesses 
opens a new and promising scenario for a better comprehension of the molecular basis 
underlying the above pathological conditions. There is, however, an urgent need for more 
studies to deeply understand i) how DLG1 abundance and cell distribution are deregulated, 
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ii) which specific functions or interactions are altered and iii) how these changes impact on 
the pathogenesis. A more complete knowledge on the transcriptional control, especially the 
role of unexplored transcription factors, and epigenetic and posttranscriptional regulation will 
provide new insights about the control of DLG1 abundance. This knowledge, added to new 
data on signal transduction pathways that may post-translationally modify DLG1 localization, 
would aid to clarify specific pathogenic mechanisms and, eventually, to define therapeutic 
targets or diagnosis biomarkers. In addition, further high-throughput studies are necessary for 
a much clearer comprehension of the real incidence and relevance of DLG1 gene mutations, 
as underlying genetic changes of specific neurological disorders and probably autoimmune 
diseases.  
In summary, the understanding gained during the last years opened a plethora of new 
possibilities for dissecting mechanisms involved in the development of significant 
pathologies, with not only uncertain biological etiology, but also with the lack of a rapid 
diagnosis and effective therapies. Further analysis in the area would be extremely valuable to 
overcome these global health concerns. 
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Figure legends 
 
Figure 1 Alterations in DLG1 expression are associated to different human pathologies. 
(A) Loss of DLG1 normal cell localization at the cell borders and changes in its abundance 
are observed during epithelial tumor development at diverse anatomical sites. (B) Different 
neurological diseases are linked to diverse genetic mutations in the DLG1 gene and probably 
to changes in DNA methylation status. (C) Redistribution of DLG1 in T-lymphocytes with 
loss of its expression at the immunological synapses can deregulate signaling pathways, 
driving to inflammatory illnesses. 
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Figure 2 Mechanisms controlling DLG1 expression at different levels.  
(A) Transcriptional level. A schematic representation of DLG1 promoter region shows both 
putative (AP-1, AP-2, NF-kB and SP-1) and demonstrated interacting transcription factors 
(Snai1 and ZNF191). The green and red lines indicate transcriptional activation or repression, 
respectively. Regions enriched with CpG dinucleotides are indicated by blue arrowheads. (B) 
Post-transcriptional level. The 5´UTR of DLG1 mRNA includes the non-coding exons A, B 
and part of exon C. The alternative splicing of exon B, that gives rise to the short mRNA 
variant, is represented. The translational efficiency of unspliced and spliced variants is 
indicated by blue arrows. (C) Post-translational level. The relative localization of 
phosphorylation sites relative to modular interacting domains are indicated by yellow stars. 
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